Form 8-K - Current report:
SEC Accession No. 0001193125-22-085974
Filing Date
2022-03-28
Accepted
2022-03-28 08:10:02
Documents
14
Period of Report
2022-03-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d262798d8k.htm   iXBRL 8-K 25997
2 EX-99.1 d262798dex991.htm EX-99.1 13322
6 GRAPHIC g262798g0326050829448.jpg GRAPHIC 2334
  Complete submission text file 0001193125-22-085974.txt   172962

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inab-20220328.xsd EX-101.SCH 2842
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inab-20220328_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inab-20220328_pre.xml EX-101.PRE 11698
8 EXTRACTED XBRL INSTANCE DOCUMENT d262798d8k_htm.xml XML 3443
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39692 | Film No.: 22773245
SIC: 2836 Biological Products, (No Diagnostic Substances)